Integrated in vivo genetic and pharmacologic screening identifies co-inhibition of EGRF and ROCK as a potential treatment regimen for triple-negative breast cancer.

Furthermore, compared to each inhibitor alone, the inhibitory growth effect of the combination on orthotopic tumors formed by HCC1806 cells was enhanced, however did not reach statistical significance (Figure 4C ).

also in 111,027 other papers